Sanofi

OverviewSuggest Edit

Sanofi is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions. It operates in three core business units: Specialty Care, Vaccines, and General Medicines. The Specialty Care business unit focuses on rare diseases, multiple sclerosis, oncology, immunology, and rare blood disorders. The Vaccines business unit primarily operates through Sanofi Pasteur, a key supplier of life-saving vaccines in both developed and emerging markets. The General Medicines business unit offers treatments for diabetes, cardiovascular, as well as established products. The company also comprises Consumer Healthcare (CHC), a standalone business unit with integrated research, development, manufacturing, support, and information technology capabilities.
TypePublic
Founded2004
HQParis, FR
Websitesanofi.com
Employee Ratings3.9
Overall CultureA-

Latest Updates

Employees (est.) (Dec 2021)95,442(-3%)
Job Openings2,230
Revenue (FY, 2021)€37.8 B(+5%)
Share Price (May 2022)€102.4(-1%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Sanofi

Paul Hudson

Paul Hudson

Chief Executive Officer & Director
Serge Weinberg

Serge Weinberg

Chairman of the Board of Directors
Olivier Charmeil

Olivier Charmeil

Executive Vice President, General Medicines
Natalie Bickford

Natalie Bickford

Executive Vice President, Chief People Officer
Julie van Ongevalle

Julie van Ongevalle

Executive Vice President, Consumer Healthcare
Bill Sibold

Bill Sibold

Executive Vice President Sanofi Genzyme; President, Sanofi North America
Show more

Sanofi Office Locations

Sanofi has offices in Paris, Ambarès-et-Lagrave, Amilly, Antony and in 109 other locations
Paris, FR (HQ)
54 Rue la Boétie
Ambarès-et-Lagrave, FR
1 Rue de la Vierge
Amilly, FR
196 Rue du Maréchal Juin
Amilly, FR
748 Rue du Maréchal Juin
Antony, FR
20 Avenue Raymond Aron
Chilly-Mazarin, FR
1 Avenue Pierre Brossolette
Show all (119)

Sanofi Financials and Metrics

Sanofi Revenue

Sanofi's revenue was reported to be €37.76 b in FY, 2021
EUR

Revenue (Q1, 2022)

9.7b

Gross profit (Q1, 2022)

7.6b

Net income (Q1, 2022)

2.0b

EBITDA (Q1, 2022)

2.9b

EBIT (Q1, 2022)

2.4b

Market capitalization (27-May-2022)

128.5b

Closing stock price (27-May-2022)

102.4

EV

128.5b
Sanofi's current market capitalization is €128.5 b.
Annual
EURFY, 2019FY, 2020FY, 2021

Revenue

36.1b36.0b37.8b

Cost of goods sold

(10.3b)(10.5b)(10.7b)

Gross profit

28.7b27.5b28.9b

R&D expense

(6.0b)(5.5b)(5.7b)
Quarterly
EURQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Revenue

8.4b8.6b9.5b9.0b8.2b9.5b8.6b8.7b10.4b9.7b

Cost of goods sold

(2.6b)(1.9b)(3.1b)(2.9b)(1.5b)(3.2b)(2.7b)(1.9b)(3.2b)(2.9b)

Gross profit

6.2b7.7b7.0b6.7b14.5b7.0b6.5b7.3b7.9b7.6b

R&D expense

(1.4b)(1.6b)(1.4b)(1.3b)(1.4b)(1.3b)(1.3b)(1.4b)(1.4b)(1.5b)
Annual
EURFY, 2019FY, 2020FY, 2021

Cash

9.4b13.9b10.1b

Accounts Receivable

7.9b7.5b7.6b

Prepaid Expenses

1.9b2.4b2.0b

Inventories

8.0b8.4b8.7b
Quarterly
EURQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Cash

6.7b16.0b9.7b

Accounts Receivable

7.2b7.2b6.8b

Prepaid Expenses

623.0m

Inventories

8.4b8.9b9.3b
Annual
EURFY, 2019FY, 2020FY, 2021

Net Income

2.6b12.0b6.2b

Depreciation and Amortization

7.5b

Inventories

(547.0m)(593.0m)(357.0m)

Accounts Payable

169.0m86.0m451.0m
Quarterly
EURQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Net Income

968.0m968.0m9.0b9.0b2.8b2.8b

Depreciation and Amortization

3.8b3.8b2.0b2.0b1.7b1.7b

Inventories

(934.0m)(934.0m)(1.0b)(1.0b)(821.0m)(821.0m)

Accounts Payable

(49.0m)(49.0m)(325.0m)(325.0m)(89.0m)(89.0m)
Show all financial metrics

Sanofi Operating Metrics

FY, 2018FY, 2019

Production Sites

7573

R&D Centers

2020

Suppliers

86 k68 k

Projects in R&D Pipeline

8191

Sanofi Acquisitions / Subsidiaries

Company NameDateDeal Size
AmunixDecember 20, 2021$1 b
OrigimmDecember 01, 2021
KadmonSeptember 08, 2021$1.9 b
Translate BioAugust 03, 2021$3.2 b
Tidal TherapeuticsApril 09, 2021$160 m
KymabJanuary 11, 2021$1.1 b
Kiadis PharmaNovember 02, 2020€308 m
Principia BioPharmaAugust 17, 2020$3.4 b
SynthorxDecember 09, 2019$2.5 m
AblynxJanuary 29, 2018$4.8 b
Show more

Sanofi Revenue Breakdown

Embed Graph

Sanofi revenue breakdown by business segment: 11.8% from HEALTH CARE DIVERSIFIED, 71.4% from PHARMACEUTICALS and 16.7% from VACCINES

Human Capital Metrics

Embed Graph

Sanofi Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

SecurityScorecard logo

Sanofi Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Sanofi Online and Social Media Presence

Embed Graph

Sanofi Company Culture

  • Overall Culture

    A-

    75/100

  • CEO Rating

    A

    77/100

  • Compensation

    A-

    76/100

  • Diversity

    A-

    76/100

Learn more on Comparably

Sanofi News and Updates

Global Osteoarthritis (IA Injections, NSAIDs & Analgesics) Market Research Report 2022-2026 Featuring Johnson & Johnson, Novartis, Bayer, GlaxoSmithKline, Pfizer and Sanofi

DUBLIN, May 18, 2022 /PRNewswire/ -- The "Global Osteoarthritis Market (IA Injections, NSAIDs & Analgesics): Insights, Trends & Forecast (2022-2026)" report has been added to ResearchAndMarkets.com's offering. The global osteoarthritis market revenues are forecasted to touch US$12.14...

Insights on the Opioids Global Market to 2030 - Featuring Purdue Pharma, AstraZeneca and Sanofi Among Others

DUBLIN, May 6, 2022 /PRNewswire/ -- The "Opioids Market by Product Type and Application: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering. The global opioids market was valued at $4,412.48 million in 2020, and is...

IGM Biosciences Announces Closing of Global Collaboration Agreement with Sanofi

$150 Million Payment to IGM from Sanofi $150 Million Payment to IGM from Sanofi

Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi

SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that its partner S…

Sanofi India Q1 Review - Beat On Margins; Strong Recovery Sequentially: Nirmal Bang

Sanofi India Q1 Review - Beat On Margins; Strong Recovery Sequentially: Nirmal Bang

Sanofi posts higher earnings and sales, sees further growth ahead

Sanofi posts higher earnings and sales, sees further growth ahead
Show more

Sanofi Frequently Asked Questions

  • When was Sanofi founded?

    Sanofi was founded in 2004.

  • Who are Sanofi key executives?

    Sanofi's key executives are Paul Hudson, Serge Weinberg and Olivier Charmeil.

  • How many employees does Sanofi have?

    Sanofi has 95,442 employees.

  • What is Sanofi revenue?

    Latest Sanofi annual revenue is €37.8 b.

  • What is Sanofi revenue per employee?

    Latest Sanofi revenue per employee is €395.6 k.

  • Who are Sanofi competitors?

    Competitors of Sanofi include Viatris, AstraZeneca and Eli Lilly.

  • Where is Sanofi headquarters?

    Sanofi headquarters is located at 54 Rue la Boétie, Paris.

  • Where are Sanofi offices?

    Sanofi has offices in Paris, Ambarès-et-Lagrave, Amilly, Antony and in 109 other locations.

  • How many offices does Sanofi have?

    Sanofi has 119 offices.